LUCA Science develops innovative treatments intended for mitochondrial and related diseases.
LUCA Science has raised $29.2M in total funding. The most recent round was Series B. The last funding was announced in June 2022.
LUCA Science's investors include Nissay Capital, SMBC Venture Capital, Fast Track Initiative, Inc., 4BIO Capital, Nippon Venture Capital.
LUCA Science is headquartered in Tokyo, Japan.
LUCA Science develops innovative treatments intended for mitochondrial and related diseases.
LUCA Science is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"LUCA Science — Funding & Investors." VCBacked, June 6, 2022, https://www.vcbacked.co/company/luca-science. Accessed September 29, 2026.
VCBacked. (2022). LUCA Science — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/luca-science
{{cite web |title=LUCA Science — Funding & Investors |url=https://www.vcbacked.co/company/luca-science |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated